113 related articles for article (PubMed ID: 32965247)
1. ; PARAMETERS OF FIBRINOLYTIC AND ANTIFIBRINOLYTIC ACTIVITY IN PATIENTS WITH ALCOHOLIC LIVER CIRRHOSIS ASSOCIATED WITH ADIPOSITY.
Virstiuk N; Matkovska N
Georgian Med News; 2020; (304-305):37-43. PubMed ID: 32965247
[TBL] [Abstract][Full Text] [Related]
2. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
3. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
4. The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents.
Sudi KM; Gallistl S; Tröbinger M; Payerl D; Weinhandl G; Muntean W; Aigner R; Borkenstein MH
J Pediatr Endocrinol Metab; 2001 Jan; 14(1):85-94. PubMed ID: 11220710
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein (a) and fibrinolytic system in liver cirrhosis. Coagulation Abnormalities in Liver Cirrhosis (CALC) Study Group.
Cimminiello C; Soncini M; Gerosa MC; Toschi V; Motta A; Bonfardeci G
Biomed Pharmacother; 1995; 49(7-8):364-8. PubMed ID: 8562864
[TBL] [Abstract][Full Text] [Related]
7. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
8. Profound imbalance of pro-fibrinolytic and anti-fibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type 1) and severe bleeding diathesis in a patient with cirrhosis: correction by liver transplantation.
Kahl BS; Schwartz BS; Mosher DF
Blood Coagul Fibrinolysis; 2003 Dec; 14(8):741-4. PubMed ID: 14614353
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
Watanabe R; Wada H; Miura Y; Murata Y; Watanabe Y; Sakakura M; Okugawa Y; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Shiku H; Nobori T
Clin Appl Thromb Hemost; 2001 Jul; 7(3):229-33. PubMed ID: 11441985
[TBL] [Abstract][Full Text] [Related]
10. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
[TBL] [Abstract][Full Text] [Related]
11. Hypofibrinolysis in atrial fibrillation.
Roldán V; Marín F; Marco P; Martínez JG; Calatayud R; Sogorb F
Am Heart J; 1998 Dec; 136(6):956-60. PubMed ID: 9842006
[TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B
J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
[TBL] [Abstract][Full Text] [Related]
13. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
14. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.
Huber K; Kirchheimer JC; Korninger C; Binder BR
Thromb Res; 1991 Jun; 62(5):491-500. PubMed ID: 1910213
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients: Potential Clinical Implications.
Guler N; Burleson A; Syed D; Banos A; Hopkinson W; Hoppensteadt D; Rees H; Fareed J
Clin Appl Thromb Hemost; 2016 May; 22(4):372-6. PubMed ID: 26207021
[TBL] [Abstract][Full Text] [Related]
17. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
[TBL] [Abstract][Full Text] [Related]
18. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
19. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
